We are thrilled to announce that Theodora Pappa, MD, PhD, has been awarded the 2023…
Read More
From Clinical Thyroidology® for the Public: Most children with thyroid cancer do very well as…
From Clinical Thyroidology® for the Public: A small fraction of people who have thyroid surgery…
Thyroid Cancer Survivorship: A Physician’s Own Experience Kaniksha Desai, MD, interviews Anupam Kotwal, MD, about…
From Clinical Thyroidology® for the Public: Once a cancer is diagnosed and surgery is an…
Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Thyroid cancers (TC) are driven by a handful of genetic alterations. Papillary TC primarily harbors mutations involving BRAF, RAS or RET genes.
Medullary thyroid cancer (MTC) is a rare thyroid malignancy and considered a neuroendocrine type of tumor.
There are limited number of studies that have examined patients preferences concerning treatment options for patients with thyroid cancer.
Thyroid cancer in pediatric patients is not a rare entity, in fact it is the most common non-CNS solid tumor in childhood.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.